Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 10/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20998613 | 0.82 | CASP1 (0.58) | CASP1 | |
| SCHEMBL2371550 | 0.79 | L3MBTL1 (0.61) | SMN1; SMN2CYP1A2L3MBTL1TSHR | |
| SCHEMBL29965203 | 0.79 | L3MBTL1 (0.61) | SMN1; SMN2CYP1A2L3MBTL1TSHR | |
| SCHEMBL6565184 | 0.79 | CYP1A2 (0.43) | CASP1CYP1A2L3MBTL1MAPT | |
| SCHEMBL502864 | 0.79 | CASP1 (0.50) | CASP1LMNAHTTSMN1; SMN2PTGS2 | |
| SCHEMBL146565 | 0.79 | CASP1 (0.50) | CASP1LMNAHTTSMN1; SMN2PTGS2 | |
| SCHEMBL1745319 | 0.78 | CASP1 (0.51) | CASP1PTGS2L3MBTL1PGRPOLB | |
| Ammonia Solution, Strong SCHEMBL502557 | 0.77 | CASP1 (0.49) | CASP1LMNAHTTSMN1; SMN2PTGS2 | |
| SCHEMBL11599660 | 0.77 | CASP1 (0.49) | CASP1LMNAHTTSMN1; SMN2PTGS2 | |
| SCHEMBL10849395 | 0.77 | CASP1 (0.57) | CASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018109642-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | CASP1 1319/4885LMNA 4381/4885HTT 4317/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CASP1 3215/4885LMNA 3199/4885HTT 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.